Heart failure and diabetes
New treatments for diabetes

Type 2 diabetes mellitus (T2DM) is a cardiometabolic disease that predisposes to microvascular and macrovascular complications, including heart failure (HF).
There are several mechanisms that can explain the development of HF in patients with diabetes.
Despite of receiving the standard treatment for, patients with T2DM and established cardiovascular (CV) disease still remain at risk, with a reduced life expectancy, and therefore, need an additional cardioprotective treatment. While intensive glycemic control offers a substantial benefit in terms of reduction of microvascular events, it is insufficient in terms of reducing macrovascular events, and the potential damage that occurs in the face of severe hypoglycemia can counteract the potential benefit in intensive treatment for the decrease in blood glucose. Treatments for glycemic control that improve CV factors and extend beyond their glucocentric effect are those that can improve morbidity and mortality in diabetic patients today.
The new antidiabetic drugs have tried to demonstrate CV safety, especially in the group of diabetics with high CV risk, some of them have shown a reduction in CV and total mortality.
The advent of GLP-1 agonists and SGLT2 inhibitors has opened a promising new era in type II diabetic patients.

Keywords: Diabetes; SGLT2 inhibitors; GLP-1 agonists; Cardiovascular risk; Cardiovascular mortality; Heart failure; Antidiabetics; High blood pressure